SEC Form 4 · accession 0001144204-16-079693
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Beth Taylor
Officer — Corporate Controller
Period of report
Feb 4, 2016
Accepted (ET)
Feb 8, 2016 · 8:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 4, 2016 | A | 3,750 | $0.00 | A | 17,007 | D | |
| Common StockF3 | Feb 6, 2016 | F | 525 | $3.02 | D | 16,482 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $3.18 | Feb 4, 2016 | A | 7,500 | A | — | Feb 4, 2026 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 4, 2017, in the form of one share of common stock for each restricted stock unit.
- F2Includes 652 and 978 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2015 and December 15, 2015, respectively.
- F3Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 1,356 restricted stock units in the form of Company common stock on a one-for-one basis on February 6, 2016.
- F4Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 4, 2017.